文献速递心外重症与机械循环支持

左心室辅助装置植入后行静脉-肺动脉体外生命支持作为临时右心室支持的结局

Outcomes of venopulmonary arterial extracorporeal life support as temporary right ventricular support after left ventricular assist implantation.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-06-05

本研究连续纳入112例接受HeartWare左心室辅助装置植入的患者,其中75例仅植入左心室辅助装置,23例同期联合静脉-肺动脉体外生命支持,14例接受持久性双心室辅助装置支持。静脉-肺动脉体外生命支持组术前病情最重,Interagency Registry for Mechanical Assisted Circulatory Support 1级比例最高,术后1年生存率在仅左心室辅助装置组为84%,静脉-肺动脉体外生命支持组为62%,双心室辅助装置组为64.3%。作者认为,在需要临时双心室支持的危重患者中,计划性静脉-肺动脉体外生命支持可提供与持久性双心室辅助装置支持相似的、可接受的结局。

要点

  • 静脉-肺动脉体外生命支持组术前Interagency Registry for Mechanical Assisted Circulatory Support 1级比例48%,高于仅左心室辅助装置组的19%和双心室辅助装置组的57%(P < .001)。
  • 静脉-肺动脉体外生命支持组术前需要机械支持者占43%,需要术前通气者占38%,均高于其他两组。
  • 1年生存率:仅左心室辅助装置组84%,静脉-肺动脉体外生命支持组62%,双心室辅助装置组64.3%。

核心结论

  • 在需要临时双心室支持的危重患者中,计划性静脉-肺动脉体外生命支持提供了可接受的结局,与持久性双心室辅助装置支持相似。
  • 需要静脉-肺动脉体外生命支持更多取决于术前病情严重程度,而非超声心动图或血流动力学参数。

研究设计与样本

  • 连续纳入112例接受HeartWare左心室辅助装置植入的患者,其中75例仅植入左心室辅助装置,23例同期联合静脉-肺动脉体外生命支持,14例接受持久性双心室辅助装置支持。
  • 短期或持久性双心室支持的选择基于临床特征、超声心动图和血流动力学特征。

主要发现

  • 静脉-肺动脉体外生命支持组术前Interagency Registry for Mechanical Assisted Circulatory Support 1级比例为48%,仅左心室辅助装置组为19%,双心室辅助装置组为57%(P < .001)。
  • 静脉-肺动脉体外生命支持组术前需要机械支持者占43%,仅左心室辅助装置组为9%,双心室辅助装置组为29%(P < .001);术前需要通气者分别占38%、9%和21%(P < .05)。
  • 右心房压力:仅左心室辅助装置组14.3 ± 6.7 mmHg,静脉-肺动脉体外生命支持组13.6 ± 4.8 mmHg,双心室辅助装置组18.7 ± 6.0 mmHg(P < .05)。
  • 右心房/肺毛细血管楔压比值:仅左心室辅助装置组0.53 ± 0.23,静脉-肺动脉体外生命支持组0.51 ± 0.17,双心室辅助装置组0.69 ± 0.22(P < .02)。
  • 三尖瓣反流分级:仅左心室辅助装置组1.7 ± 1.5,静脉-肺动脉体外生命支持组1.7 ± 1.6,双心室辅助装置组2.8 ± 1.6(P < .01)。

关键数值与推荐

  • 1年生存率:仅左心室辅助装置组84%,静脉-肺动脉体外生命支持组62%,双心室辅助装置组64.3%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We report our experience with temporary postoperative venopulmonary arterial extracorporeal life support as short-term right ventricular support in patients with biventricular failure undergoing HeartWare (HeartWare Inc, Framingham, Mass) left ventricular assist device implantation and compared these outcomes with isolated left ventricular assist device support and long-term biventricular assist device support. METHODS: A total of 112 consecutive patients were studied, 75 with the isolated HeartWare left ventricular assist device, 23 with a concomitant left ventricular assist device and venopulmonary arterial extracorporeal life support, and 14 with durable biventricular assist device support. The decision concerning short-term or durable biventricular support was based on the clinical characteristics, echocardiography, and hemodynamic profile. RESULTS: Patients who required venopulmonary arterial extracorporeal life support after left ventricular assist device insertion required the greatest support preoperatively and were more likely to have Interagency Registry for Mechanical Assisted Circulatory Support level 1 (left ventricular assist device 19%, venopulmonary arterial extracorporeal life support 48%, biventricular assist device 57%, P < .001). They were more likely to require preoperative mechanical support (left ventricular assist device 9%, venopulmonary arterial extracorporeal life support 43%, and biventricular assist device 29%, P < .001) or preoperative ventilation (9%, 38%, and 21%, respectively, P < .05). Preoperative echocardiographic and hemodynamic parameters were more similar to those requiring isolated left ventricular assist device, with patients requiring durable biventricular assist device support more likely to have elevated right atrial pressure (left ventricular assist device 14.3 ± 6.7 vs venopulmonary arterial extracorporeal life support 13.6 ± 4.8 vs biventricular assist device 18.7 ± 6.0 mm Hg, P < .05); right atrial/pulmonary capillary wedge pressure ratio (0.53 ± 0.23 vs 0.51 ± 0.17, vs 0.69 ± 0.22, respectively, P < .02); and tricuspid regurgitation grade (1.7 ± 1.5 vs 1.7 ± 1.6 vs 2.8 ± 1.6, respectively, P < .01). One-year survival was 84% for those with an isolated left ventricular assist device compared with 62% for those with venopulmonary arterial extracorporeal life support and 64.3% for biventricular assist device. CONCLUSIONS: In critically unwell patients requiring temporary biventricular support, planned venopulmonary arterial extracorporeal life support provides acceptable outcomes, similar to durable biventricular assist device support. Requirement for venopulmonary arterial extracorporeal life support is more determined by the level of preoperative acuity than echocardiographic or hemodynamic parameters.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Shehab S, Rao S, Macdonald P, et al. Outcomes of venopulmonary arterial extracorporeal life support as temporary right ventricular support after left ventricular assist implantation. J Thorac Cardiovasc Surg. 2018. PMID: 30025607. doi:10.1016/j.jtcvs.2018.05.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。